Overview

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effectiveness of nivolumab in patients with oral cavity cancer (OCC) who are about to undergo surgery.
Phase:
Phase 2
Details
Lead Sponsor:
David Neskey
Medical University of South Carolina
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Nivolumab